COMPASS Pathways plc (CMPS) Discusses Medical Trial Plans for PTSD and Business Preparations for Remedy-Resistant Melancholy January 7, 2026 10:00 AM EST
Firm Contributors
Stephen Schultz – Senior Vice President of Investor Relations
Kabir Nath – CEO & Director
Man Goodwin – Chief Medical Officer
Michael Gold – Chief Analysis & Improvement Officer
Steve Levine – Chief Affected person Officer
Lori Englebert – Chief Business Officer
Convention Name Contributors
Gary Small
Geoffrey Grammer
Myriam Barthes – Journey Medical, Inc.
Dimitri Cavathas
Ritu Baral – TD Cowen, Analysis Division
Paul Matteis – Stifel, Nicolaus & Firm, Integrated, Analysis Division
Gavin Clark-Gartner – Evercore ISI Institutional Equities, Analysis Division
Leonid Timashev – RBC Capital Markets, Analysis Division
Judah Frommer – Morgan Stanley, Analysis Division
Jay Olson – Oppenheimer & Co. Inc., Analysis Division
Patrick Trucchio – H.C. Wainwright & Co, LLC, Analysis Division
Thomas Shrader – BTIG, LLC, Analysis Division
Imogen Mansfield – Cantor Fitzgerald & Co., Analysis Division
Sumant Kulkarni – Canaccord Genuity Corp., Analysis Division
Dialog
Stephen Schultz
Senior Vice President of Investor Relations
Welcome all of you, and thanks for becoming a member of us right this moment for this webinar. My identify is Steve Schultz, Senior Vice President of Investor Relations at COMPASS Pathways. The decision is being recorded and will probably be obtainable for 30 days — I am sorry, the decision is being recorded and will probably be obtainable on the COMPASS Pathways Investor Relations web site shortly after the conclusion of the decision and will probably be obtainable for a interval of 30 days.
Earlier than we start, let me remind everybody that through the name right this moment, the crew will probably be making statements about future plans and prospects that represent forward-looking statements. Every forward-looking assertion
